Safety Concerns and Efficacy of Biofortunes Monoclonal Antibody for RSV Prevention

Dr. Benoon highlights the imbalance of death in the treated groups compared to the placebo groups, indicating the dangerous nature and low efficacy of Biofortunes antibody for respiratory syncytial virus (RSV) prevention. They discuss the comparison between two antibodies used in clinical trials for RSV and present data on nurse of a map (Bay Fortis), questioning its approval and lack of observed benefit for hospitalization. Concerns about the lack of convincing efficacy and mortality signal with nurse in the map or Bayfortis in newborns are discussed, as well as the ongoing clinical trials and role of regulatory agencies.